Clinical Trials Browser

Phase 2 × Carcinoma, Non-Small-Cell Lung × dacomitinib × Clear all

Carcinoma, Non-Small-Cell Lung

NCT04946968 2025-06-11

Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers

Phase 2 Active not recruiting

24 enrolled

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT04675008 2021-01-05

Central Nervous System(CNS) Efficacy of Dacomitinib

Phase 2 Unknown

30 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04339829 2020-04-09

An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

Phase 2 Unknown

50 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00548093 2019-05-21

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

Phase 2 Completed

66 enrolled 19 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01465802 2019-01-09

ARCHER 1042

Phase 2 Completed

236 enrolled 24 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01858389 2017-07-18

A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer

Phase 2 Completed

41 enrolled 16 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00769067 2015-10-07

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

Phase 2 Completed

188 enrolled 14 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

Clinical Trials

Phase 2 Study of Dacomitinib in NSCLC

Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers

Central Nervous System(CNS) Efficacy of Dacomitinib

An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

ARCHER 1042

A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen